Tirzepatide dosing follows the same core principle as the rest of the class — start low, escalate slowly, and let tolerability set the pace — but the specific ladder, the range of maintenance doses, and the missed-dose window are all distinct from semaglutide. This clinician-focused guide lays out the full titration protocol for weight management: the starting dose and escalation cadence, the four-week rule, how to select a maintenance dose, managing tolerability during escalation, missed-dose handling, and a quick-reference dosing chart.
It is a practical companion to our complete prescriber’s guide to GLP-1 medications for weight management, and pairs naturally with the semaglutide dosing and titration guide for prescribers choosing between the two agents.
For chronic weight management, tirzepatide (Zepbound®) starts at 2.5 mg once weekly (U.S. Food and Drug Administration, 2026). This starting dose is for treatment initiation only — it is not a therapeutic maintenance dose and is not expected to produce meaningful weight loss on its own. Its job is to introduce the drug gently and let the gastrointestinal system adapt before the effective doses begin.
After four weeks at 2.5 mg, the dose increases to 5 mg once weekly, and from there it can be escalated in 2.5 mg increments as needed and tolerated, with at least four weeks at each step. The cadence is deliberate: because tirzepatide activates both the GIP and GLP-1 receptors and slows gastric emptying, moving too quickly is the most common driver of nausea and early discontinuation (Drucker, 2018).
The full tirzepatide titration ladder for weight management runs through six dose levels: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg once weekly. Each increase should follow a minimum of four weeks at the current dose.
Mapped to a timeline, that looks like 2.5 mg for weeks 1–4, 5 mg for weeks 5–8, and then optional increases to 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each held for at least four weeks before the next step. The four-week rule is a floor, not a schedule to rush. There is no clinical prize for reaching 15 mg quickly; the right pace is the one the patient tolerates. Tirzepatide for type 2 diabetes (Mounjaro®) uses the same escalation and the same 15 mg maximum, so take care not to confuse products or indications.
Unlike semaglutide, which has a single weight-management maintenance dose, tirzepatide offers three: 5 mg, 10 mg, or 15 mg once weekly. This flexibility is clinically useful — it lets you land a patient at the lowest dose that delivers adequate results while remaining comfortable.
Higher doses generally produce greater average weight loss; in the SURMOUNT-1 trial the 15 mg dose produced approximately 21% mean weight reduction (Jastreboff et al., 2022), and in the head-to-head SURMOUNT-5 trial tirzepatide outperformed semaglutide on average weight loss (Aronne et al., 2025). But more is not automatically better for every patient. Some achieve their goals and tolerate 5 or 10 mg well and never need to reach 15 mg. Choose the maintenance dose based on response and tolerability, not on hitting the ceiling.
One maintenance nuance worth flagging: Zepbound® also carries an indication for moderate-to-severe obstructive sleep apnea in adults with obesity, and for that indication the recommended maintenance doses are 10 mg or 15 mg only — 5 mg is not among them. If a weight-management patient also has treated OSA and you are documenting to the OSA indication, the maintenance target is higher than it would be for weight reduction alone.
The titration schedule is a default that you are meant to adjust. If a patient is struggling at a given dose — ongoing nausea, vomiting, or significant GI distress — the right move is to hold at that dose for additional weeks before advancing, or to step back down to the last well-tolerated dose and try again later.
Practical counseling reduces most problems: smaller meals, eating slowly, stopping at the first sign of fullness, staying hydrated, and easing off fatty or very large meals. Setting the expectation early — that some nausea during dose increases is common and usually temporary — keeps patients on therapy through the adjustment period. Because adherence is what ultimately produces weight loss, a comfortable patient on a lower dose almost always does better than an uncomfortable one pushed to the maximum. Knowing when to hold, when to step back, and how to coach a patient through the first uncomfortable weeks is a clinical skill that improves with experience and with structured education such as IAPAM’s CME-accredited GLP-1 prescribing training, which turns these judgment calls into a repeatable protocol rather than trial and error.
Tirzepatide has a specific, clearly defined missed-dose window. If a weekly dose is missed, it can be administered as soon as possible within four days (96 hours) of the missed dose. If more than four days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day (U.S. Food and Drug Administration, 2026).
Note that this four-day rule is specific to tirzepatide and differs from semaglutide’s window — another reason not to apply one product’s rules to another. Patients may also change their weekly dosing day if needed, as long as at least three days (72 hours) separate two doses. For longer interruptions, use clinical judgment about whether to resume at the same dose or step back and re-titrate.
Verify before you prescribeDose strengths, maintenance options and missed-dose language in this class have been revised more than once since 2022. Confirm the current FDA-approved prescribing information for the specific product on the day you prescribe, and date-stamp any titration handout you give staff or patients.
This tirzepatide dosing chart summarizes the weight-management titration ladder. Always verify against current labeling.
| Timing | Dose (once weekly) | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Initiation only — not a maintenance dose |
| Weeks 5–8 | 5 mg | First potential maintenance dose |
| Weeks 9–12 | 7.5 mg | Optional step up |
| Weeks 13–16 | 10 mg | Potential maintenance dose |
| Weeks 17–20 | 12.5 mg | Optional step up |
| Week 21+ | 15 mg | Maximum and potential maintenance dose |
| Maintenance options | 5, 10, or 15 mg | Choose by response and tolerability |
| Missed dose | — | Take within 4 days; if more than 4 days, skip and resume schedule |
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
Tirzepatide (Zepbound®) starts at 2.5 mg once weekly for four weeks, then increases to 5 mg, and can step up in 2.5 mg increments — 7.5, 10, 12.5, and up to 15 mg — with at least four weeks at each dose.
The maximum dose for both weight management (Zepbound®) and type 2 diabetes (Mounjaro®) is 15 mg once weekly. The recommended maintenance doses for weight management are 5 mg, 10 mg, or 15 mg.
No. The 2.5 mg dose is for treatment initiation only and is not intended as a maintenance dose. It is a ramp-up step to improve tolerability before therapeutic doses begin.
If the missed dose is caught within four days (96 hours), it can be administered as soon as possible. If more than four days have passed, skip it and resume on the regular schedule. Doses should be at least three days apart.
Tirzepatide uses a 2.5–15 mg ladder with three maintenance options (5, 10, 15 mg) and a four-day missed-dose window. Semaglutide (Wegovy®) tops out at 2.4 mg weekly with a single maintenance dose. The two products should never be dosed interchangeably.
On average, higher doses tend to produce greater weight loss, but not for every patient. Many do well and tolerate 5 or 10 mg without needing 15 mg. The best maintenance dose is the lowest one that achieves the goal comfortably.
Tirzepatide dosing is a patient, stepwise process: a 2.5 mg initiation dose, four-week increments up to a 15 mg ceiling, three maintenance options to fine-tune, and a distinct four-day missed-dose rule. Prescribers who respect the titration and individualize the maintenance dose get strong results with fewer dropouts.
For the full clinical workflow, pair this with our complete prescriber’s guide to GLP-1 medications. And to build titration, dosing, and safety protocols with confidence, IAPAM’s CME GLP-1 titration and prescribing course — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — gives you ready-made clinical frameworks. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.
Explore GLP-1 Certification Training →
Disclaimer: This article is for informational and educational purposes only and does not constitute medical or prescribing advice. Dosing and labeling change; always verify the current FDA-approved prescribing information for the specific product before prescribing.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.